Kelun Biotech to Present Study Results of Cancer Drugs at American Oncology Meeting
Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) will present the results of its registrational studies on sacituzumab tirumotecan (sac-TMT) and lunbotinib fumarate at the 2026 American Society of Clinical Oncology annual meeting, according to a filing by parent Sichuan Kelun Pharmaceutical (SHE:002422) with the Shenzhen bourse.Its study on its sacituzumab tirumotecan drug versus pembrolizumab for advanced non-small cell lung cancer treatment showed a higher response rate for its sac-TMT against pembrolizumab, the filing said.The company will also present results from its study on lunbotinib, which showed an objective response rate of 87.1% on patients with RET-fusion positive non-small cell lung cancer in patients with prior chemotherapy.
